what this node claims
AlphaFold metrics / MCHR1
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
54%
low debt pressure
21%
84%structurestrong
pLDDT 84.43
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 84.43
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 84.43
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
353 residues / min 21.73 / max 98.56 / source alphafold db
Very high
63.5%
224 residues / >=90
Confident
20.4%
72 residues / 70-89
Low
6.8%
24 residues / 50-69
Very low
9.3%
33 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 353 of 353 residues.
- residues 1-39 / mean 35.94
- residues 327-336 / mean 57.7
- residues 69-74 / mean 55.9
- residues 352-353 / mean 59.09
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.